Regression of Pulmonary Lymphangioleiomyomatosis (PLAM)-associated Retroperitoneal Angiomyolipoma Post-Lung Transplantation With Rapamycin Treatment

Journal of Heart and Lung Transplantation

Volumn 27, Issue 4, 2008, Pages 462-465

  Morton, Judith M ^a,b   McLean, Catriona ^a   Booth, Stephen S ^a   Snell, Gregory I ^a,b   Whitford, Helen M ^a,b  

^a MONASH UNIVERSITY   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

RAPAMYCIN;

ADULT; ANGIOMYOLIPOMA; ARTICLE; BIOPSY TECHNIQUE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG INHIBITION; EXPERIMENTAL STUDY; FEMALE; FOLLOW UP; HEMOPTYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; LOW DRUG DOSE; LUNG TRANSPLANTATION; LYMPHANGIOLEIOMYOMATOSIS; PRIORITY JOURNAL; PULMONARY LYMPHANGIOLEIOMYOMATOSIS; REMISSION; RETROPERITONEAL ANGIOMYOLIPOMA; RETROPERITONEUM; TUMOR CELL;

ADULT; ANGIOMYOLIPOMA; ANTIBIOTICS, ANTINEOPLASTIC; BIOPSY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LUNG NEOPLASMS; LUNG TRANSPLANTATION; LYMPHANGIOLEIOMYOMATOSIS; NEOPLASMS, SECOND PRIMARY; POSTOPERATIVE PERIOD; RETROPERITONEAL NEOPLASMS; SIROLIMUS; SURGERY, COMPUTER-ASSISTED; TOMOGRAPHY, X-RAY COMPUTED;

EID: 40949158793     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2008.01.005     Document Type: Article

References (25)

1. Trulock E.P., Edwards L.B., Taylor D.O., et al. Registry of the International Society for Heart and Lung Transplantation: twenty-second official adult lung and heart-lung transplant report-2005. J Heart Lung Transplant 24 (2005) 956-967
2. Nine J.S., Yousem S.A., Paradis I.L., Keenan R., and Griffith B.P. Lymphangioleiomyomatosis: recurrence after lung transplantation. J Heart Lung Transplant 13 (1994) 714-719
3. O'Brien J.D., Lium J.H., Parosa J.F., et al. Lymphangiomyomatosis recurrence in the allograft after single-lung transplantation. Am J Respir Crit Care Med 151 (1995) 2033-2036
4. Boehler A. Lung transplantation for cystic lung diseases: lymphangioleiomyomatosis, histiocytosis X, and sarcoidosis. Semin Respir Crit Care Med 22 (2001) 509-516
5. Bittmann I., Dose T.B., Muller C., et al. Lymphangioleiomyomatosis: recurrence after single lung transplantation. Hum Pathol 28 (1997) 1420-1423
6. Avila N.A., Kelly J.A., Chu S.C., Dwyer A.J., and Moss J. Lymphangioleiomyomatosis: abdominopelvic CT and US findings. Radiology 216 (2000) 147-153
7. Smolarek T.A., Wessner L.L., McCormack F.X., et al. Evidence that lymphangiomyomatosis is caused by TSC2 mutations: chromosome 16p13 loss of heterozygosity in angiomyolipomas and lymph nodes from women with lymphangiomyomatosis. Am J Hum Genet 62 (1998) 810-815
8. Carsillo T., Astrinidis A., and Henske E.P. Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis. Proc Natl Acad Sci USA 97 (2000) 6085-6090
9. Yu J., Astrinidis A., and Henske E.P. Chromosome 16 loss of heterozygosity in tuberous sclerosis and sporadic lymphangiomyomatosis. Am J Respir Crit Care Med 164 (2001) 1537-1540
10. Goncharova E.A., Goncharov D.A., Eszterhas A., et al. Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation. A role for the TSC2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis (LAM). J Biol Chem 277 (2002) 30958-30967
11. Schmelzle T., and Hall M.N. TOR, a central controller of cell growth. Cell 103 (2000) 253-262
12. El-Hashemite N., Zhang H., Henske E.P., and Kwiatkowski D.J. Mutation in TSC2 and activation of mammalian target of rapamycin signalling pathway in renal angiomyolipoma. Lancet 361 (2003) 1348-1349
13. Kahan B.D., and Camardo J.S. Rapamycin: clinical results and future opportunities. Transplantation 72 (2001) 1181-1193
14. Kenerson H.L., Aicher L.D., True L.D., and Yeung R.S. Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors. Cancer Res 62 (2002) 5645-5650
15. Kenerson H., Dundon T.A., and Yeung R.S. Effects of rapamycin in the Eker rat model of tuberous sclerosis complex. Pediatr Res 57 (2005) 67-75
16. Dervaux T., Caillard S., Meyer C., et al. Is sirolimus responsible for proteinuria?. Transplant Proc 37 (2005) 2828-2829
17. Ruiz J.C., Diekmann F., Campistol J.M., et al. Evolution of proteinuria after conversion from calcineurin inhibitors (CNI) to sirolimus (SRL) in renal transplant patients: a multicenter study. Transplant Proc 37 (2005) 3833-3835
18. McWilliams T.J., Levvey B.J., Russell P.A., Milne D.G., and Snell G.I. Interstitial pneumonitis associated with sirolimus: a dilemma for lung transplantation. J Heart Lung Transplant 22 (2003) 210-213
19. Snell G.I., Levvey B.J., Chin W., et al. Sirolimus allows renal recovery in lung and heart transplant recipients with chronic renal impairment. J Heart Lung Transplant 21 (2002) 540-546
20. Snell G.I., Levvey B.J., Chin W., et al. Rescue therapy: a role for sirolimus in lung and heart transplant recipients. Transplant Proc 33 (2001) 1084-1085
21. Snell G.I., Valentine V.G., Vitulo P., et al. Everolimus versus azathioprine in maintenance lung transplant recipients: an international, randomized, double-blind clinical trial. Am J Transplant 6 (2006) 169-177
22. Kovarik J.M., Snell G.I., Valentine V., et al. Everolimus in pulmonary transplantation: pharmacokinetics and exposure-response relationships. J Heart Lung Transplant 25 (2006) 440-446
23. Kauffman H.M., Cherikh W.S., Cheng Y., Hanto D.W., and Kahan B.D. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 80 (2005) 883-889
24. Kahan B.D., Yakupoglu Y.K., Schoenberg L., et al. Low incidence of malignancy among sirolimus/cyclosporine-treated renal transplant recipients. Transplantation 80 (2005) 749-758
25. Yousem S.A., Berry G.J., Cagle P.T., et al. Revision of the 1990 working formulation for the classification of pulmonary allograft rejection. J Heart Lung Transplant 15 (1996) 1-15